2024/08/07 22:00:00 | |
---|---|
Price | |
0.325 USD | |
Difference | -6.23% (-0.02) |
ISIN | NL0014040206 |
Symbol | 39K |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.35 USD (1,200) |
Ask (Ask size) | 0.373 USD (100) |
Open | 0.429 USD |
High | 0.429 USD |
Low | 0.32 USD |
Close (prev. day) | 0.3466 USD |
VWAP | 0.498857 USD |
Volume (pcs) | 8,358,256 |
Trading volume | 4,171,002.82 |
Number of trades | 15,228 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/08/07 22:00:00 | |
---|---|
Price | |
0.325 USD | |
Difference | -6.23% (-0.02) |
ISIN | NL0014040206 |
Symbol | 39K |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.35 USD (1,200) |
Ask (Ask size) | 0.373 USD (100) |
Open | 0.429 USD |
High | 0.429 USD |
Low | 0.32 USD |
Close (prev. day) | 0.3466 USD |
VWAP | 0.498857 USD |
Volume (pcs) | 8,358,256 |
Trading volume | 4,171,002.82 |
Number of trades | 15,228 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | -70.89% | -67.50% | -97.12% |
Perf (abs.) | -0.79 | -0.68 | -10.95 |
Beta | - | - | - |
Volatility | 93.82 | 84.12 | 103.19 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.323 USD (1,713,242) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.418 USD (325,389) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.465 USD (217,207) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.838 USD (99,617) |
YTD High | date | 1.250 USD (2024/01/16) |
YTD Low | date | 0.251 USD (2024/07/31) |
52 Weeks High | date | 1.530 USD (2023/10/31) |
52 Weeks Low | date | 0.251 USD (2024/07/31) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2024/09/18 | 08:02 | 0.1456 EUR | 0.00 | 1 |
Nasdaq | 2024/08/07 | 22:00 | 0.325 USD | 4.17 | 15,228 |
Munich | 2024/09/18 | 08:03 | 0.2495 EUR | 0.00 | 1 |
Hamburg | 2024/09/18 | 08:16 | 0.10 EUR | 0.00 | 1 |
Frankfurt | 2024/08/20 | 16:47 | 0.20 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/09/18 | 15:30 | 0.20 USD | 0.00 | 3 |
Duesseldorf | 2024/08/09 | 09:30 | 0.2995 EUR | 0.00 | 2 |
Berlin | 2024/09/18 | 15:39 | 0.2165 EUR | 0.00 | 11 |
CENTOGENE NV |
- - |
Am Strande 7 - 18055 Rostock |
Telefon: +49-381-80113400 |
Fax: +381-80113401 |
E-mail: - |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
Kim Stratton | Chairman of Managing Board |
Ian Rentsch | Member of Executive Committee |
Miguel Coego Rios | Member of Executive Committee |
Peter Bauer | Member of Executive Committee |
Peer Schatz | Chairman of Supervisory Board |
Eric Souêtre | Member of Supervisory Board |
Hubert Birner | Member of Supervisory Board |
Jonathan Sheldon | Member of Supervisory Board |
Guido Prehn | Member of Supervisory Board |
Mary Sheahan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer